This study is testing a new liquid treatment called UGN-103 for people with a specific type of early-stage bladder cancer that has a moderate risk of returning. The treatment is placed directly into the bladder once a week for six weeks. Researchers want to see if it can complete…
Phase: PHASE3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC